India is a leading contributor to the global Tuberculosis burden. India shares 27%
of the global burden.
Out of 1,30,000
MDR-TB
(multidrug-resistant Tuberculosis) patients, only 660
patients are on Bedaquiline.
Bedaquiline is a drug used to treat TB patients that are multidrug resistant. The government relies on a USAID donation (United States Agency for International Development) via an American pharmaceutical company Janssen. This is however limited to patients living in a 5 kilometer radius of 6 designated hospitals.